December 3rd 2021
An overview of therapies used as prophylaxis against chemotherapy-induced neutropenia and projections on improving quality of life for patients with solid tumors with therapeutic advances.
A panel of oncologists react to their interest in using plinabulin as prophylaxis against chemotherapy-induced neutropenia in future clinical practice.
November 12th 2021
An overview of the design and results of the PROTECTIVE-1 study of plinabulin versus pegfilgrastim in patients with solid tumors receiving docetaxel myelosuppressive chemotherapy.
Considerations regarding the potential to prevent chemotherapy-induced neutropenia with newer therapeutic strategies as well as changes to treatment dosages.
Recommendations regarding how to best manage patients who experience bone pain from chemotherapy-induced neutropenia prophylaxis with growth factor support.
November 5th 2021
Preventive therapies and factors that impact how to best mitigate chemotherapy-induced neutropenia in patients with breast cancer.
October 29th 2021
Recommendations for intervening with growth factor support and important considerations for reducing or discontinuing anti-cancer therapy when patients show signs of neutropenia.
Advantages, in terms of safety and efficacy, of granulocyte colony-stimulating factors used as prophylaxis against chemotherapy-induced neutropenia.
October 22nd 2021
Breast oncologists react to the availability of granulocyte colony-stimulating factors, used as prophylaxis against chemotherapy-induced neutropenia.
A panel of breast oncologists define chemotherapy-induced neutropenia in terms of how they assess risk and attempt to prevent treatment-related toxicities in patients with cancer.
January 27th 2021